SYNSIGHT France

SYNSIGHT developed the first drug discovery platform combining cell-based microscopy that train AI models, to generate new chemical entities. Your benefits will be to increase the productivity of your R&D and secure your drug discovery programs.

Our innovative platform and our technologies can be directly applied to protein-protein or protein-RNA interactions. Our bioassay is unique and patented and is able to qualify and quantify these interactions directly in human cell, and also of course the efficacy of small molecule modulators (Hit identification, "in cell IC50" measurement). This assay, easy to setup as medium or high-throughput screening level, is then able to train our AI models which generate new molecules.

We already successfully used our platform to study oncologic and neurodegenerative targets, for our own R&D or for customers. Our platform is able to manage different therapeutic area (oncology, virology, neurology, …), and different targets from your portfolio. We also propose to feed your portfolio and develop screening setup of our platform with exclusivity, with innovative targets like TPD-43, YB-1, alpha-SYN, BCL2, HUR, …
Website:
www.synsight.net
Company Size (Fulltime employees)
Year of foundation
2013
Partnering Objectives
Please specify your partnering goal
We propose to our partners to use our drug discovery platformes for their R&D projects, espacially agains protein-protein and protein-RNA interactions.
Headquartner in China
Dr. Cyril Bauvais
Dr. Cyril Bauvais
CEO 
Functionality

Terra Magnum Capital China

Founded in 2016 with over $800 million assets under management, Terra Magnum Capital Partners ("TMCP" or "the firm") is a China-focused private equity firm specialized in both direct investments and fund investments.
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
deal seeking
Headquartner in China
Ms. Annie Liu
Analyst 

Theramix United States

Theramix is developing imaging technology for diagnosis and imaging-based drug discovery and development. We have established a rapid drug testing platform for quickly assessing the efficacy and toxicity of drugs in animals. A cancer drug has been developed guided by in vivo imaging approaches. The new drug is designed to control tumor growth to make cancer manageable. Animal experiments show promising data on the cure of cancer with this drug.
Company Size (Fulltime employees)
Year of foundation
2012
Please specify your partnering goal
fundraising
Headquartner in China
Biotech/Pharma Category
zuyong Xia
ceo 

TMD Pharmaceutical Research United States

Dear Prospect Customer:

I would like to introduce my company (TDM Pharmaceutical Research, Inc) to you. TDM Pharmaceutical Research, INC, is a highly productive, intensely focused, quality-oriented CRO; we are experienced, well established, and driven by scientific merit. As a full-service GLP and GCP compliant laboratory, TDM offers a variety of discovery, research, development, bioanalytical, and consulting services to support discovery and development of pharmaceutical and chemical products. We pride ourselves on prompt data turnaround and addressing our clients’ needs with the accuracy and quality that are critical to their businesses.

TDM is uniquely different from other CROs: our over 90 years of combined industry experience allows us to resolve complex issues by providing comprehensive solutions in pharmacokinetics, toxicokinetics, pharmacokinetic/pharmacodynamic correlations, and more.

We are experienced in both the sponsor and the CRO position, so we anticipate and address the needs of our clients. Resourceful, committed personnel provide proactive support throughout each project, and respond to potential issues immediately.

Our myriad clients include both companies and individuals in the pharmaceutical and related industries. By selecting TDM as the partner for your next project, you will find we take each job and its needs personally; our focus is always on the client!

If you have any question, please feel free to contact me at: changfu.cheng@tdmrxresearch.com, or phone at 1-774-258-2425.

Thanks!

 

Changfu Cheng, PhD

President

TDM Pharmaceutical Research, Inc

https://tdmpharmalab.com

Company Size (Fulltime employees)
Year of foundation
1996
Please specify your partnering goal
IND of our drug candidates
Headquartner in China
Biotech/Pharma Category
Assets Information 1
FLUORINE- AND/OR DEUTERIUM-CONTAINING COMPOUNDS FOR TREATING NON-SMALL CELL LUNG CANCER AND RELATED DISEASES, US patent 10,633,367
Assets Information 2
DEUTERATED COMPOUNDS FOR TREATING FABRY, GAUCHER, PARKINSON’S AND RELATED DISEASES AND CONDITIONS, AND COMPOSITIONS AND METHODS THEREOF. US patent 10,519,157
Biotech/Pharma Asset Stage
Slides Deck
(pdf, 802.42KB)
Changfu Cheng
President 
Functionality

TomoWave Laboratories, Inc United States

TomoWave is developing a new medical imaging modality of optoacoustic tomography, using ultrasound generated by laser light to provide doctors the capability to solve numerous problems in cancer diagnostics, surgery and minimally invasive therapy.
Website:
tomowave.com
Company Size (Fulltime employees)
Year of foundation
2020
Please specify your partnering goal
Find strategic partner and investors
Headquartner in China
Medtech Category
Medtech Information 1
ARIA, Maestro, Symphony|Biomedical imaging system for molecular, functional and anatomical imaging|USA, CANADA, AUSTRALIA, EUROPE, JAPAN, KOREA, CHINA
Medtech Development Stage
Aleksey Krylov
CFO 
Functionality

Topwin pharma China

Currently, TopWin Pharma. has developed to a high-tech group involving the biological and chemical medicine. TopWin Pharmaceutical Group's business has covered all aspects of R&D of new drugs, including clinical research, registration, production and sale. With the mission of "bringing benefits to mankind through innovation and technology", Topwin Group has been cooperating with well-known domestic and international drug R&D institutions to build TopWin Pharma. into a leading domestic and world-class pharmaceutical enterprise.
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Oncology domain, clinical phase innovative project
Headquartner in China
Miss Ocean Chen
BDM 

University of Edinburgh United Kingdom

University
Website:
Ed.ac.uk
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
/
Headquartner in China
Miss Guiyun Qiu

University of Houston United States

It is a University
Website:
uh.edu
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
I am a part of an organization of medical students
Headquartner in China
Biotech/Pharma Category
Mrs. Loren Gordon
student 
Functionality

University of Southern California United States

Private university in U.S.
Company Size (Fulltime employees)
Partnering Objectives
Please specify your partnering goal
Learning
Headquartner in China
Medtech Category
Chang Chang
MBA student 
Functionality

VERIGRAFT AB Sweden

VERIGRAFT AB is a Swedish biotechnology company with a unique, breakthrough technology in the field of advanced therapies and regenerative medicine. We make transplantation possible without the severe risks of immunosuppression, and develop advanced therapies and tissue engineered products that will be able to help millions of patients with serious diseases.
Company Size (Fulltime employees)
Year of foundation
2014
Partnering Objectives
Please specify your partnering goal
Looking for interested investors
Headquartner in China
Biotech/Pharma Category
Assets Information 1
Personalized tissue engineered vein||Chronic venous insufficiency|All major countries incl China
Biotech/Pharma Asset Stage
Dr. Petter Bjorquist
CEO 
Functionality